COST ANALYSIS AND FACTORS AFFECTING THE TREATMENT OF BREAST CANCER CHEMOTHERAPY PATIENTS JAMKESMAS HOSPITAL IN DR Sardjito
ABSTRACT: Main problem in treating cancer is great cost and long therapy time. It does not only result in economic loss for patients but also for their family and government. Objective of this research is to identify average cost of patient therapy and highest cost component, chemotherapy regiment pattern and its average cost, and factors influencing therapy cost in breast cancer medication on Jamkesmas patient hospitalized in Dr Sardjito Hospital, Yogyakarta. It is analytic observational research. Data was taken with retrospective method by tracing claim file and medication cost data from January to June 2011 at the Treasury and Fund Mobilization Section of Dr Sardjito Hospital. The data was analyzed using correlation analysis and linear regression. The result indicates that average costs of mild chemotheraphy (C-14-13-I), moderate chemotheraphy (C-14-13-II), and severe chemotheraphy (C-14-13-III) therapies were Rp 2.781.424,55± 2.030.016,03, Rp 4.026.695± 2.566.522,57 and 3.945.466,67 ± 3.121.163,05 respectively with the highest cost component was on drug cost/BMHP. Chemotherapy regiments used were cyclophosphamidedoxorubicin 80.88%, doxorubicin- paclitaxsel 8.82%, paclitaxsel 7.35%, doxorubicin 1.47%, cisplatin- paclitaxsel 1.47% with highest average cost was on cisplatin- paclitaxsel combination (Rp 6.546.500,00). LOS and secondary diagnosis influence significantly breast cancer chemotherapy cost of Jamkesmas patients hospitalized in Dr. Sardjito Hospital.
